Clinical significance and applications of oscillometry

David A. Kaminsky; Shannon J. Simpson; Kenneth I. Berger; Peter Calverley; Pedro L. de Melo; Ronald Dandurand; Raffaele L. Dellacà; Claude S. Farah; Ramon Farré; Graham L. Hall; Iulia Ioan; Charles G. Irvin; David W. Kaczka; Gregory G. King; Hajime Kurosawa; Enrico Lombardi; Geoffrey N. Maksym; François Marchal; Ellie Oostveen; Beno W. Oppenheimer; Paul D. Robinson; Maarten van den Berge; Cindy Thamrin

doi:10.1183/16000617.0208-2021

Clinical significance and applications of oscillometry

David A. Kaminsky, Shannon J. Simpson, Kenneth I. Berger, Peter Calverley, Pedro L. de Melo, Ronald Dandurand, Raffaele L. Dellacà, Claude S. Farah, Ramon Farré, Graham L. Hall, Iulia Ioan, Charles G. Irvin, David W. Kaczka, Gregory G. King, Hajime Kurosawa, Enrico Lombardi, Geoffrey N. Maksym, François Marchal, Ellie Oostveen, Beno W. OppenheimerPaul D. Robinson, Maarten van den Berge, Cindy Thamrin

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

119 Citas (Scopus)

Resumen

Recently, “Technical standards for respiratory oscillometry” was published, which reviewed the physiological basis of oscillometric measures and detailed the technical factors related to equipment and test performance, quality assurance and reporting of results. Here we present a review of the clinical significance and applications of oscillometry. We briefly review the physiological principles of oscillometry and the basics of oscillometry interpretation, and then describe what is currently known about oscillometry in its role as a sensitive measure of airway resistance, bronchodilator responsiveness and bronchial challenge testing, and response to medical therapy, particularly in asthma and COPD. The technique may have unique advantages in situations where spirometry and other lung function tests are not suitable, such as in infants, neuromuscular disease, sleep apnoea and critical care. Other potential applications include detection of bronchiolitis obliterans, vocal cord dysfunction and the effects of environmental exposures. However, despite great promise as a useful clinical tool, we identify a number of areas in which more evidence of clinical utility is needed before oscillometry becomes routinely used for diagnosing or monitoring respiratory disease.

Idioma original	English
Número de artículo	210208
Publicación	European Respiratory Review
Volumen	31
N.º	163
DOI	https://doi.org/10.1183/16000617.0208-2021
Estado	Published - mar. 31 2022

Nota bibliográfica

Funding Information:
Conflict of interest: D.A. Kaminsky reports personal payments made as faculty speaker for Cardiorespiratory Diagnostics Seminar from MGC Diagnostics, Inc. outside the submitted work. Past Chair of ATS Proficiency Standards for Pulmonary Function Laboratories Committee, unpaid. S.J. Simpson has nothing to disclose. K.I. Berger has nothing to disclose. P. Calverley reports receiving consulting fees paid by Phillips Respironics for advisory work on a novel COPD ventilator. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Phillips Respironics, outside the submitted work. P.L. de Melo reports patent 28727 issued. R.J. Dandurand reports grants or contracts paid to the institution from AstraZeneca, Boehringer-Ingelheim, Covis Pharma, Grifols, MGC Diagnostics, Teva Pharma, Thorasys, and Vyaire, outside the submitted work. Speaking payment from Novartis for L’oscillométrie en clinique: qu’ajoute-t-elle aux évaluations pulmonaires?, 18 September 2019, Boehringer-Ingelheim for L’oscillométrie: vieille physiologie avec un avenir brilliant, 17 November 2020, and Latin American Respiratory Physiology Society for Oscillometry in Asthma and COPD: Interpretation Strategies, 14 November 2020, outside the submitted work. Chairman, Oscillometry Harmonisation Study Group, an international committee academic and industry experts working to standardise oscillometry devices, and Chairman, Respiratory Effectiveness Group Technologies Working Group, Cambridge, U.K. (https://www.regresearchnetwork.org). R.L. Dellacà reports royalties or licenses from Restech, Philips and Vyaire. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Restech and Philips, outside the submitted work. Support for attending meetings from Philips and Vyaire. Patent issued, owned and licensed from Politecnico di Milano University. Member of the Board of Directors for Restech. Stocks owned for Restech. Free loan of equipment for studies received from Vyaire and Restech. C.S. Farah has nothing to disclose. R. Farré has nothing to disclose. G.L. Hall has nothing to disclose. I. Ioan has nothing to disclose. C.G. Irvin received consulting fees from Medical Graphics Corporation, outside the submitted work. D.W. Kaczka reports support for the present manuscript from University of Iowa. Grants or contracts from Dept of Defence and NIH, outside the submitted work. Consulting fees received from ZOLL Medical, Inc. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from CHEST, ASME, Medical Society of New Zealand, and Johns Hopkins University, outside the submitted work. US patent 10,675,423 B2 (patent on MFOV technique, inventor) and PCT patent pending, patent on MFOV technique pending. Stock or stock options held for OscillaVent, Inc. Loan of ventilator for other projects from ZOLL Medical Inc. G.G. King reports grants or contracts from Restech Italy, NHMRC, Boehringer Ingelheim, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma, Philanthropic individuals and societies, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma and Novartis, outside the submitted work. Leadership or fiduciary role in other board, society, committee or advocacy group for ERS Technical Standards for Respiratory Oscillometry. H. Kurosawa reports receiving a grant from CHEST Co. Ltd. Royalties or licence for CHEST Co. Ltd. Payment or honoraria for lectures received from CHEST Co. Ltd. Nippon, Boehringer Ingelheim, Novartis, and Teijin Pharma, outside the submitted work. E. Lombardi reports grants or contracts from Restech and Sanofi, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Angelini, Chiesi, GSK, Novartis and Sanofi, outside the submitted work. Participation on a Data Safety Monitoring Board or Advisory Board for GSK and Novartis. G.N. Maksym reports grants or contracts from National Research Council of Canada, Cyclomedica Inc. Australia, and Lung Association of Nova Scotia, outside the submitted work. Accommodation Expenses received from Thorasys, Thoracic Medical Systems Inc. for attending European Society Meeting 2019. Patents planned, issued or pending for Method and system to acquire oscillometry measurements, owned by Thorasys, Thoracic Medical Systems Inc. Stock or stock options held for Thorasys, Thoracic Medical Systems Inc. F. Marchal has nothing to disclose. E. Oostveen has nothing to disclose. B.W. Oppenheimer has nothing to disclose. P.D. Robinson has nothing to disclose. M. van den Berge reports grants or contracts from GlaxoSmithKline, Novartis, Astra Zeneca, Roche, and Genentech, outside the submitted work. C. Thamrin report grants or contracts from Restech SRL and THORASYS Thoracic. Equipment on loan for research studies from Restech SRL and THORASYS Thoracic, outside the submitted work.

Publisher Copyright:
© The authors 2022.

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine

PubMed: MeSH publication types

Journal Article
Review

Acceder al documento

10.1183/16000617.0208-2021

Otros archivos y enlaces

Citar esto

Kaminsky, D. A., Simpson, S. J., Berger, K. I., Calverley, P., de Melo, P. L., Dandurand, R., Dellacà, R. L., Farah, C. S., Farré, R., Hall, G. L., Ioan, I., Irvin, C. G., Kaczka, D. W., King, G. G., Kurosawa, H., Lombardi, E., Maksym, G. N., Marchal, F., Oostveen, E., ... Thamrin, C. (2022). Clinical significance and applications of oscillometry. European Respiratory Review, 31(163), Artículo 210208. https://doi.org/10.1183/16000617.0208-2021

Kaminsky, DA, Simpson, SJ, Berger, KI, Calverley, P, de Melo, PL, Dandurand, R, Dellacà, RL, Farah, CS, Farré, R, Hall, GL, Ioan, I, Irvin, CG, Kaczka, DW, King, GG, Kurosawa, H, Lombardi, E, Maksym, GN, Marchal, F, Oostveen, E, Oppenheimer, BW, Robinson, PD, van den Berge, M & Thamrin, C 2022, 'Clinical significance and applications of oscillometry', European Respiratory Review, vol. 31, n.º 163, 210208. https://doi.org/10.1183/16000617.0208-2021

@article{96d575cb1af345119683afd8d55dcd40,

title = "Clinical significance and applications of oscillometry",

abstract = "Recently, “Technical standards for respiratory oscillometry” was published, which reviewed the physiological basis of oscillometric measures and detailed the technical factors related to equipment and test performance, quality assurance and reporting of results. Here we present a review of the clinical significance and applications of oscillometry. We briefly review the physiological principles of oscillometry and the basics of oscillometry interpretation, and then describe what is currently known about oscillometry in its role as a sensitive measure of airway resistance, bronchodilator responsiveness and bronchial challenge testing, and response to medical therapy, particularly in asthma and COPD. The technique may have unique advantages in situations where spirometry and other lung function tests are not suitable, such as in infants, neuromuscular disease, sleep apnoea and critical care. Other potential applications include detection of bronchiolitis obliterans, vocal cord dysfunction and the effects of environmental exposures. However, despite great promise as a useful clinical tool, we identify a number of areas in which more evidence of clinical utility is needed before oscillometry becomes routinely used for diagnosing or monitoring respiratory disease.",

author = "Kaminsky, {David A.} and Simpson, {Shannon J.} and Berger, {Kenneth I.} and Peter Calverley and {de Melo}, {Pedro L.} and Ronald Dandurand and Dellac{\`a}, {Raffaele L.} and Farah, {Claude S.} and Ramon Farr{\'e} and Hall, {Graham L.} and Iulia Ioan and Irvin, {Charles G.} and Kaczka, {David W.} and King, {Gregory G.} and Hajime Kurosawa and Enrico Lombardi and Maksym, {Geoffrey N.} and Fran{\c c}ois Marchal and Ellie Oostveen and Oppenheimer, {Beno W.} and Robinson, {Paul D.} and {van den Berge}, Maarten and Cindy Thamrin",

note = "Funding Information: Conflict of interest: D.A. Kaminsky reports personal payments made as faculty speaker for Cardiorespiratory Diagnostics Seminar from MGC Diagnostics, Inc. outside the submitted work. Past Chair of ATS Proficiency Standards for Pulmonary Function Laboratories Committee, unpaid. S.J. Simpson has nothing to disclose. K.I. Berger has nothing to disclose. P. Calverley reports receiving consulting fees paid by Phillips Respironics for advisory work on a novel COPD ventilator. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Phillips Respironics, outside the submitted work. P.L. de Melo reports patent 28727 issued. R.J. Dandurand reports grants or contracts paid to the institution from AstraZeneca, Boehringer-Ingelheim, Covis Pharma, Grifols, MGC Diagnostics, Teva Pharma, Thorasys, and Vyaire, outside the submitted work. Speaking payment from Novartis for L{\textquoteright}oscillom{\'e}trie en clinique: qu{\textquoteright}ajoute-t-elle aux {\'e}valuations pulmonaires?, 18 September 2019, Boehringer-Ingelheim for L{\textquoteright}oscillom{\'e}trie: vieille physiologie avec un avenir brilliant, 17 November 2020, and Latin American Respiratory Physiology Society for Oscillometry in Asthma and COPD: Interpretation Strategies, 14 November 2020, outside the submitted work. Chairman, Oscillometry Harmonisation Study Group, an international committee academic and industry experts working to standardise oscillometry devices, and Chairman, Respiratory Effectiveness Group Technologies Working Group, Cambridge, U.K. (https://www.regresearchnetwork.org). R.L. Dellac{\`a} reports royalties or licenses from Restech, Philips and Vyaire. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Restech and Philips, outside the submitted work. Support for attending meetings from Philips and Vyaire. Patent issued, owned and licensed from Politecnico di Milano University. Member of the Board of Directors for Restech. Stocks owned for Restech. Free loan of equipment for studies received from Vyaire and Restech. C.S. Farah has nothing to disclose. R. Farr{\'e} has nothing to disclose. G.L. Hall has nothing to disclose. I. Ioan has nothing to disclose. C.G. Irvin received consulting fees from Medical Graphics Corporation, outside the submitted work. D.W. Kaczka reports support for the present manuscript from University of Iowa. Grants or contracts from Dept of Defence and NIH, outside the submitted work. Consulting fees received from ZOLL Medical, Inc. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from CHEST, ASME, Medical Society of New Zealand, and Johns Hopkins University, outside the submitted work. US patent 10,675,423 B2 (patent on MFOV technique, inventor) and PCT patent pending, patent on MFOV technique pending. Stock or stock options held for OscillaVent, Inc. Loan of ventilator for other projects from ZOLL Medical Inc. G.G. King reports grants or contracts from Restech Italy, NHMRC, Boehringer Ingelheim, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma, Philanthropic individuals and societies, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma and Novartis, outside the submitted work. Leadership or fiduciary role in other board, society, committee or advocacy group for ERS Technical Standards for Respiratory Oscillometry. H. Kurosawa reports receiving a grant from CHEST Co. Ltd. Royalties or licence for CHEST Co. Ltd. Payment or honoraria for lectures received from CHEST Co. Ltd. Nippon, Boehringer Ingelheim, Novartis, and Teijin Pharma, outside the submitted work. E. Lombardi reports grants or contracts from Restech and Sanofi, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Angelini, Chiesi, GSK, Novartis and Sanofi, outside the submitted work. Participation on a Data Safety Monitoring Board or Advisory Board for GSK and Novartis. G.N. Maksym reports grants or contracts from National Research Council of Canada, Cyclomedica Inc. Australia, and Lung Association of Nova Scotia, outside the submitted work. Accommodation Expenses received from Thorasys, Thoracic Medical Systems Inc. for attending European Society Meeting 2019. Patents planned, issued or pending for Method and system to acquire oscillometry measurements, owned by Thorasys, Thoracic Medical Systems Inc. Stock or stock options held for Thorasys, Thoracic Medical Systems Inc. F. Marchal has nothing to disclose. E. Oostveen has nothing to disclose. B.W. Oppenheimer has nothing to disclose. P.D. Robinson has nothing to disclose. M. van den Berge reports grants or contracts from GlaxoSmithKline, Novartis, Astra Zeneca, Roche, and Genentech, outside the submitted work. C. Thamrin report grants or contracts from Restech SRL and THORASYS Thoracic. Equipment on loan for research studies from Restech SRL and THORASYS Thoracic, outside the submitted work. Publisher Copyright: {\textcopyright} The authors 2022.",

year = "2022",

month = mar,

day = "31",

doi = "10.1183/16000617.0208-2021",

language = "English",

volume = "31",

journal = "European Respiratory Review",

issn = "0905-9180",

publisher = "European Respiratory Society",

number = "163",

}

TY - JOUR

T1 - Clinical significance and applications of oscillometry

AU - Kaminsky, David A.

AU - Simpson, Shannon J.

AU - Berger, Kenneth I.

AU - Calverley, Peter

AU - de Melo, Pedro L.

AU - Dandurand, Ronald

AU - Dellacà, Raffaele L.

AU - Farah, Claude S.

AU - Farré, Ramon

AU - Hall, Graham L.

AU - Ioan, Iulia

AU - Irvin, Charles G.

AU - Kaczka, David W.

AU - King, Gregory G.

AU - Kurosawa, Hajime

AU - Lombardi, Enrico

AU - Maksym, Geoffrey N.

AU - Marchal, François

AU - Oostveen, Ellie

AU - Oppenheimer, Beno W.

AU - Robinson, Paul D.

AU - van den Berge, Maarten

AU - Thamrin, Cindy

N1 - Funding Information: Conflict of interest: D.A. Kaminsky reports personal payments made as faculty speaker for Cardiorespiratory Diagnostics Seminar from MGC Diagnostics, Inc. outside the submitted work. Past Chair of ATS Proficiency Standards for Pulmonary Function Laboratories Committee, unpaid. S.J. Simpson has nothing to disclose. K.I. Berger has nothing to disclose. P. Calverley reports receiving consulting fees paid by Phillips Respironics for advisory work on a novel COPD ventilator. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Phillips Respironics, outside the submitted work. P.L. de Melo reports patent 28727 issued. R.J. Dandurand reports grants or contracts paid to the institution from AstraZeneca, Boehringer-Ingelheim, Covis Pharma, Grifols, MGC Diagnostics, Teva Pharma, Thorasys, and Vyaire, outside the submitted work. Speaking payment from Novartis for L’oscillométrie en clinique: qu’ajoute-t-elle aux évaluations pulmonaires?, 18 September 2019, Boehringer-Ingelheim for L’oscillométrie: vieille physiologie avec un avenir brilliant, 17 November 2020, and Latin American Respiratory Physiology Society for Oscillometry in Asthma and COPD: Interpretation Strategies, 14 November 2020, outside the submitted work. Chairman, Oscillometry Harmonisation Study Group, an international committee academic and industry experts working to standardise oscillometry devices, and Chairman, Respiratory Effectiveness Group Technologies Working Group, Cambridge, U.K. (https://www.regresearchnetwork.org). R.L. Dellacà reports royalties or licenses from Restech, Philips and Vyaire. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Restech and Philips, outside the submitted work. Support for attending meetings from Philips and Vyaire. Patent issued, owned and licensed from Politecnico di Milano University. Member of the Board of Directors for Restech. Stocks owned for Restech. Free loan of equipment for studies received from Vyaire and Restech. C.S. Farah has nothing to disclose. R. Farré has nothing to disclose. G.L. Hall has nothing to disclose. I. Ioan has nothing to disclose. C.G. Irvin received consulting fees from Medical Graphics Corporation, outside the submitted work. D.W. Kaczka reports support for the present manuscript from University of Iowa. Grants or contracts from Dept of Defence and NIH, outside the submitted work. Consulting fees received from ZOLL Medical, Inc. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from CHEST, ASME, Medical Society of New Zealand, and Johns Hopkins University, outside the submitted work. US patent 10,675,423 B2 (patent on MFOV technique, inventor) and PCT patent pending, patent on MFOV technique pending. Stock or stock options held for OscillaVent, Inc. Loan of ventilator for other projects from ZOLL Medical Inc. G.G. King reports grants or contracts from Restech Italy, NHMRC, Boehringer Ingelheim, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma, Philanthropic individuals and societies, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma and Novartis, outside the submitted work. Leadership or fiduciary role in other board, society, committee or advocacy group for ERS Technical Standards for Respiratory Oscillometry. H. Kurosawa reports receiving a grant from CHEST Co. Ltd. Royalties or licence for CHEST Co. Ltd. Payment or honoraria for lectures received from CHEST Co. Ltd. Nippon, Boehringer Ingelheim, Novartis, and Teijin Pharma, outside the submitted work. E. Lombardi reports grants or contracts from Restech and Sanofi, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Angelini, Chiesi, GSK, Novartis and Sanofi, outside the submitted work. Participation on a Data Safety Monitoring Board or Advisory Board for GSK and Novartis. G.N. Maksym reports grants or contracts from National Research Council of Canada, Cyclomedica Inc. Australia, and Lung Association of Nova Scotia, outside the submitted work. Accommodation Expenses received from Thorasys, Thoracic Medical Systems Inc. for attending European Society Meeting 2019. Patents planned, issued or pending for Method and system to acquire oscillometry measurements, owned by Thorasys, Thoracic Medical Systems Inc. Stock or stock options held for Thorasys, Thoracic Medical Systems Inc. F. Marchal has nothing to disclose. E. Oostveen has nothing to disclose. B.W. Oppenheimer has nothing to disclose. P.D. Robinson has nothing to disclose. M. van den Berge reports grants or contracts from GlaxoSmithKline, Novartis, Astra Zeneca, Roche, and Genentech, outside the submitted work. C. Thamrin report grants or contracts from Restech SRL and THORASYS Thoracic. Equipment on loan for research studies from Restech SRL and THORASYS Thoracic, outside the submitted work. Publisher Copyright: © The authors 2022.

PY - 2022/3/31

Y1 - 2022/3/31

N2 - Recently, “Technical standards for respiratory oscillometry” was published, which reviewed the physiological basis of oscillometric measures and detailed the technical factors related to equipment and test performance, quality assurance and reporting of results. Here we present a review of the clinical significance and applications of oscillometry. We briefly review the physiological principles of oscillometry and the basics of oscillometry interpretation, and then describe what is currently known about oscillometry in its role as a sensitive measure of airway resistance, bronchodilator responsiveness and bronchial challenge testing, and response to medical therapy, particularly in asthma and COPD. The technique may have unique advantages in situations where spirometry and other lung function tests are not suitable, such as in infants, neuromuscular disease, sleep apnoea and critical care. Other potential applications include detection of bronchiolitis obliterans, vocal cord dysfunction and the effects of environmental exposures. However, despite great promise as a useful clinical tool, we identify a number of areas in which more evidence of clinical utility is needed before oscillometry becomes routinely used for diagnosing or monitoring respiratory disease.

AB - Recently, “Technical standards for respiratory oscillometry” was published, which reviewed the physiological basis of oscillometric measures and detailed the technical factors related to equipment and test performance, quality assurance and reporting of results. Here we present a review of the clinical significance and applications of oscillometry. We briefly review the physiological principles of oscillometry and the basics of oscillometry interpretation, and then describe what is currently known about oscillometry in its role as a sensitive measure of airway resistance, bronchodilator responsiveness and bronchial challenge testing, and response to medical therapy, particularly in asthma and COPD. The technique may have unique advantages in situations where spirometry and other lung function tests are not suitable, such as in infants, neuromuscular disease, sleep apnoea and critical care. Other potential applications include detection of bronchiolitis obliterans, vocal cord dysfunction and the effects of environmental exposures. However, despite great promise as a useful clinical tool, we identify a number of areas in which more evidence of clinical utility is needed before oscillometry becomes routinely used for diagnosing or monitoring respiratory disease.

UR - http://www.scopus.com/inward/record.url?scp=85124254539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124254539&partnerID=8YFLogxK

U2 - 10.1183/16000617.0208-2021

DO - 10.1183/16000617.0208-2021

M3 - Review article

C2 - 35140105

AN - SCOPUS:85124254539

SN - 0905-9180

VL - 31

JO - European Respiratory Review

JF - European Respiratory Review

IS - 163

M1 - 210208

ER -

Clinical significance and applications of oscillometry

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto